DeBakey Cardiovascular Magnetic Resonance Study

Conditions

Cardiovascular Diseases

Keywords

Cardiovascular Disease, Cardiac Magnetic Resonance, Myocardial Fibrosis, Valvular Heart Disease, Ischemic Heart Disease, Cardiomyopathy

Brief summary

While advancements in cardiac magnetic resonance (CMR) have improved image quality, it is unclear how these improvements are connected to the clinical evaluation of individuals with cardiovascular disease. The aim of this large prospective registry revolves around 4 key principles: 1) utilize CMR to gain additional pathophysiologic insights into cardiovascular disease, 2) understand how CMR compares to alternative cardiovascular diagnostic modalities, 3) determine how CMR affects clinical management decisions, and 4) establish a link between CMR findings and long term prognosis in patients with known or suspected cardiovascular disease. The ultimate aim is to utilize CMR to improve patient outcomes. CMR techniques to be studies include function, fibrosis, and flow. Focus areas include valvular heart disease, ischemic heart disease, cardiomyopathies, and vascular disease.

Detailed description

Patient Population, Recruitment, and Consent: Patients presenting to the Houston Methodist DeBakey CMR Laboratory will be enrolled from April 2008 to April 2038. It is expected that up to 100,000 patients may be enrolled during this period. Subjects will be identified based on their referral to the Houston Methodist DeBakey CMR Laboratory for MRI studies during the proposed study period. After enrollment, a registered nurse or physician will perform a thorough structured patient interview and/or review of electronic health records to document baseline medical history including cardiac risk factors, symptoms, medication usage, and prior procedure history. A small blood sample will be drawn and stored for future biomarker and/or genetic testing analysis. Annual follow up for clinical status will be performed via review of electronic health records; structured telephone interviews with the patients, relatives, and/or their health care providers; and/or the social security death index database.

Malahfji M, Nguyen DT, Bhugra P, Crudo V, Saeed M, Goel SS, Reardon MJ, Kleiman NS, Zoghbi WA, Graviss EA, Shah DJ.

2025-08-051 citations

10.1016/j.jcmg.2025.04.010

Cardiac MRI Evaluation of Determinants and Prognostic Implications of Right Ventricular Dysfunction in Aortic Regurgitation.

Malahfji M, Bhugra P, Nguyen DT, Crudo V, Saeed M, Reardon M, Nagueh SF, Zoghbi WA, Graviss EA, Shah DJ.

2025-02-01

10.1148/ryct.230389

Association of secondary mitral regurgitation and right ventricular dysfunction among patients with non-ischaemic cardiomyopathy

Bhupendar Tayal, Nadeen Faza, Duc T. Nguyen, Maan Malahfji, Stephen B. Little et al. (11 authors)

European Heart Journal - Cardiovascular Imaging2024-05-232 citations

10.1093/ehjci/jeae134

Extracellular Volume in Primary Mitral Regurgitation.

Kitkungvan D, Yang EY, El Tallawi KC, Nagueh SF, Nabi F, Khan MA, Nguyen DT, Graviss EA, Lawrie GM, Zoghbi WA, Bonow RO, Quinones MA, Shah DJ.

2020-12-1639 citations

10.1016/j.jcmg.2020.10.010

Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure.

Tayal B, Debs D, Nabi F, Malahfji M, Little SH, Reardon M, Zoghbi W, Kleiman N, Shah DJ.

2020-12-1621 citations

10.1016/j.jcmg.2020.11.004

Interventions

DIAGNOSTIC_TESTCardiovascular Magnetic Resonance

Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* All patients presenting to the Houston Methodist CMR Laboratory with known or suspected cardiovascular disease.

Exclusion criteria

* Unable to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Left Ventricular and/or Right Ventricular Assist Device Implantation	Through study completion, an average of once a year, up to 20 years	—
Mortality	Through study completion, an average of once a year, up to 20 years	All-cause mortality, Cardiovascular mortality (acute Myocardial Infarction, sudden death, heart failure, cerebrovascular, procedural), and Non-cardiovascular mortality
Heart Failure	Through study completion, an average of once a year, up to 20 years	Congestive heart failure
Heart and/or Lung Transplantation	Through study completion, an average of once a year, up to 20 years	—

Secondary

Measure	Time frame	Description
Cardiac Interventions	Through study completion, an average of once a year, up to 20 years	Implantable cardioverter-defibrillator (ICD), pacemakers, cardiac resynchronization therapy, coronary revascularization, valvular intervention, shunt closure
Arrhythmic	Through study completion, an average of once a year	Sustained ventricular tachycardia, ventricular fibrillation, nonfatal cardiac arrest, appropriate ICD therapy
Acute myocardial infarction	Through study completion, an average of once a year, up to 20 years	—
Acute Cerebrovascular Accident	Through study completion, an average of once a year, up to 20 years	—

Countries

United States

Contacts

Primary ContactRachel Kronman-Gross, BS

rkronman-gross@houstonmethodist.org7134416539

Backup ContactMohamad Ghosn, PhD

mghosn@houstonmethodist.org7134419837

Outcome results

None listed